echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Order of treatment of choice for BRAFV600 mutant metastatic melanoma

    J Clin Oncol: Order of treatment of choice for BRAFV600 mutant metastatic melanoma

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    PD-1/CTLA-4 combined blockade and BRAF/MEK double inhibition have shown significant clinical benefit


    In a Phase 3 clinical trial, untreated BRAFV600 mutant metastatic melanoma was randomly divided into two groups, the first step receiving nalvozumab + ipizumab (group A) or dalafinil + trametinib (group B), and after the progression of the disease, proceeding to the second step, switching to a treatment regimen, dalafinil + trametinib (group C) or nalvozumab + ipizumab (group D).



    A total of 265 patients were recruited and 73 were enrolled in the second step of treatment (27 in group C and 46 in group D


    In summary, if necessary, nivolumab plus ipizumab followed by BRAF and MEK inhibitors may be the order


     

    Original Source:

    Michael B.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.